Author: Olema Oncology

Posted Date:

May 12, 2026

Olema Oncology Reports First Quarter 2026 Financial and Operating Results

Olema Oncology

May 12, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology

May 4, 2026
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

Olema Oncology

April 29, 2026
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

Olema Oncology

April 21, 2026
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Olema Oncology

April 17, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology

April 2, 2026
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Olema Oncology

March 17, 2026
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Olema Oncology

March 16, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology

March 3, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology

February 25, 2026